BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This collaboration marks an important step forward for BioCryst in expanding the global market presence of its core products.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Dow Jones Top Markets Headlines at 1 AM ET: U.S. Stocks Down as Oil, Yield Shock Continues | What ...
Dow Jones•2026/09/16 05:00
Investment appeal stands out after pullback! Canadian pipeline giant Enbridge (ENB.US) upgraded by BMO Capital to "Outperform"
BMO has upgraded Enbridge's rating to "Outperform", believing that its recent pullback and $41 billion project backlog offer a good investment opportunity.
智通财经•2026/09/16 04:21
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Dow Jones•2026/09/16 04:10
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Dow Jones•2026/09/16 04:10
